Abstract:Antibody-drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to the payload. By combining the specificity of mABs with the high potency of the payloads, ADCs constitute a smart drug delivery system with improved therapeutic index. After recognition and binding of the mAB to its target surface antigen, ADCs are internalized by endocytosis by the tumor cell, releasing the payloads into the cytoplasm, where they exert their cytotoxic activity, eventually leading to cell death. The composition of some of the new ADCs confers additional functional properties that allow expanding their activity to neighboring cells not expressing the target antigen, constituting a valuable strategy to overcome tumor heterogeneity. Some of these 'off-target effects', such as the bystander effect, are possibly the mechanism underlying the antitumor activity demonstrated in patients with low expression of the target antigens, which represents an important paradigm shift in anticancer targeted therapy. Three ADCs are currently approved for the treatment of breast cancer (BC); two anti-HER2 (human epidermal growth factor receptor 2) ADCs (trastuzumab emtansine and trastuzumab deruxtecan); and one Trop-2-targeted ADC (sacituzumab govitecan). Based on the unprecedented efficacy data demonstrated by these agents, ADCs have been incorporated as part of standard regimens for all subtypes of advanced BC, as well as for high-risk early HER2-positive BC. Despite the remarkable advances, several hurdles still remain to overcome, including the development of reliable biomarkers for patient selection, prevention, and management of potentially severe toxicities, ADC resistance mechanisms, post-ADC resistance patterns, and optimal treatment sequencing and combinations. In this review, we will summarize the currently available evidence related to the use of these agents, as well as explore the current landscape of ADC development for BC treatment.

The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era

The target invites a foe: antibody-drug conjugates in gynecologic oncology

Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer

Advances in antibody-drug conjugates for gynecologic malignancies

Antibody-Drug Conjugates in Gynecologic Cancer

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Antibody-drug conjugates in gynecologic malignancies

The Evolving Therapeutic Landscape of Antibody-Drug Conjugates in Breast Cancer.

Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice

Antibody–drug conjugates come of age in oncology

Research progress of antibody–drug conjugates in gynecologic cancer

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Antibody-drug conjugates in solid tumors: a new frontier

Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment

ADC: a deadly killer of platinum resistant ovarian cancer

A Review of Current and Future Antibody Drug Conjugates in Breast Cancer

Antibody–Drug Conjugates—Evolution and Perspectives

Targeting cancer with antibody-drug conjugates: Promises and challenges

Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond

Progress in the study of antibody-drug conjugates for the treatment of cervical cancer